Compare Novartis AG (NVS) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs ProShares Ultra Gold ETF — how do they compare? Novartis AG trades at $142.04 (market cap $274.00B), while ProShares Ultra Gold ETF trades at $46.45 (market cap $715.43M). The key difference: Novartis AG is far larger — about 383× ProShares Ultra Gold ETF's market cap, and Novartis AG pays a 3.31% dividend while ProShares Ultra Gold ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and ProShares Ultra Gold ETF for 23 Days on average.
| NVS | UGL | |
|---|---|---|
Market Cap | $274.00B | $715.43M |
Volume | 1,852,137 | 3,002,043 |
Sector | Health | Leveraged / Inverse |
52-Week High | $168.62 | $85.62 |
52-Week Low | $121.80 | $42.79 |
Typical Hold Time | 82 Days | 23 Days |
Enterprise Value | $315.32B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
UGL stock is trading at $44.43, down 3.29% over the past day amid a broader bearish technical signal. The stock faces selling pressure with moving averages and oscillators indicating a downtrend, while key support lies at $43. Recent news highlights gold's volatility driven by shifting Federal Reserve rate expectations and Treasury yield movements, impacting sentiment.
The outlook remains cautious with technical indicators signaling bearish momentum, though oversold conditions on the 12-day RSI may offer short-term relief. Risks include persistent macroeconomic headwinds from interest rates and dollar strength, while the lack of available fundamental data limits visibility on the company's financial health and valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
